| Price | 2,020.00p on 24-04-2026 at 18:40:07 |
|---|---|
| Change | -56.00p -2.7% |
| Buy | 2,022.00p |
| Sell | 2,021.00p |
| Last Trade: | Buy 31,447.00 at 2,029.274p |
| Day's Volume: | 4,689,325 |
| Last Close: | 2,020.00p |
| Open: | 2,070.00p |
| ISIN: | GB00BN7SWP63 |
| Day's Range | 2,020.00p - 2,071.00p |
| 52wk Range: | 1,315.00p - 2,282.00p |
| Market Capitalisation: | £80.64b |
| VWAP: | 2,033.14552p |
| Shares in Issue: | 3.99b |
Glaxosmithkline (GSK) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Buy* | 31,447 | 2,029.274p | SI Trade Negotiated Trade |
16:41:02 - 24-Apr-26 |
| Sell* | 1,500 | 2,020.00p | Negotiated Trade |
16:35:01 - 24-Apr-26 |
| Sell* | 228 | 2,020.00p | SI Trade |
16:35:00 - 24-Apr-26 |
| Sell* | 103 | 2,020.00p | SI Trade |
16:35:00 - 24-Apr-26 |
| Buy* | 761 | 2,020.00p | Automatic Execution |
16:35:00 - 24-Apr-26 |
| Buy* | 3,400 | 2,020.00p | Automatic Execution |
16:35:00 - 24-Apr-26 |
| Buy* | 3,400 | 2,020.00p | Automatic Execution |
16:35:00 - 24-Apr-26 |
| Buy* | 1,724,168 | 2,020.00p | Suspected BUY Trade |
16:35:00 - 24-Apr-26 |
| Unknown* | 0 | 2,020.00p | SI Trade |
16:29:56 - 24-Apr-26 |
| Buy* | 1 | 2,022.00p | SI Trade |
16:29:50 - 24-Apr-26 |
Glaxosmithkline (GSK) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 24th Apr 2026 3:30 pm | RNS | Director/PDMR Shareholding |
| 23rd Apr 2026 7:00 am | RNS | Transaction in Own Shares |
| 22nd Apr 2026 7:00 am | RNS | Transaction in Own Shares |
| 21st Apr 2026 7:00 am | RNS | Transaction in Own Shares |
| 20th Apr 2026 3:30 pm | RNS | Director/PDMR Shareholding |
| 20th Apr 2026 7:00 am | RNS | Blenrep approved in China for 2L+ multiple myeloma |
| 20th Apr 2026 7:00 am | RNS | Transaction in Own Shares |
| 17th Apr 2026 7:00 am | RNS | Transaction in Own Shares |
| 16th Apr 2026 3:30 pm | RNS | Director/PDMR Shareholding |
| 16th Apr 2026 7:00 am | RNS | Transaction in Own Shares |